1. 249. IMPROVEMENTS AND CORRELATIONS IN ORAL ULCERS, DISEASE ACTIVITY, AND QOL IN BEHÇET'S SYNDROME PATIENTS TREATED WITH APREMILAST: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. (29th March 2019) Authors: Hatemi, Gülen; Mahr, Alfred; Takeno, Mitsuhiro; Kim, Doyoung; Melikoglu, Melike; Cheng, Sue; McCue, Shannon; Paris, Maria; Chen, Mindy; Yazici, Yusuf Journal: Rheumatology Issue: Volume 58(2019)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 250. IMPROVEMENTS IN QUALITY OF LIFE IN BEHÇET'S SYNDROME PATIENTS TREATED WITH APREMILAST: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. (29th March 2019) Authors: Hatemi, Gülen; Mahr, Alfred; Takeno, Mitsuhiro; Kim, Doyoung; Melikoglu, Melike; Cheng, Sue; McCue, Shannon; Paris, Maria; Chen, Mindy; Yazici, Yusuf Journal: Rheumatology Issue: Volume 58(2019)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study. Issue 2 (7th July 2022) Authors: Hatemi, Gülen; Mahr, Alfred; Takeno, Mitsuhiro; Kim, Doyoung; Melikoğlu, Melike; Cheng, Sue; McCue, Shannon; Paris, Maria; Chen, Mindy; Yazici, Yusuf Journal: RMD open Issue: Volume 8:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗